A Single-blind, Randomized, Placebo-controlled 3-part Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled AZD0449 Following Single and Multiple Ascending Doses and to Investigate the Anti-inflammatory Effect of Inhaled AZD0449
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs AZD 0449 (Primary) ; AZD 0449 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 26 Nov 2019 Planned number of patients changed from 174 to 120.
- 26 Nov 2019 Planned End Date changed from 11 May 2020 to 18 May 2020.
- 26 Nov 2019 Planned primary completion date changed from 11 May 2020 to 18 May 2020.